Mycophenolate mofetil in liver transplantation - Is monotherapy safe?

Clinical Transplantation

Volumn 20, Issue SUPPL. 17, 2006, Pages 75-79

  Schmeding, Maximilian ^a   Neumann, Ulf P ^a   Neuhaus, Ruth ^a   Neuhaus, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Immunosuppression; Liver transplantation; MMF; Monotherapy; Nephrotoxicity; Rejection

Indexed keywords

CALCINEURIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE; STEROID;

ANEMIA; AREA UNDER THE CURVE; ASTHENIA; BONE MARROW DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL PAIN; HEPATITIS C; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; PURINE SYNTHESIS; REVIEW; RISK REDUCTION;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 33750743723     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00604.x     Document Type: Review

References (19)

1. Wiesner RH, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Lake JR. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C. Liver Transpl 2005: 11: 750.
2. Koch RO, Graziadei IW, Schulz F et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int 2004: 17: 518.
3. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH. Bioavailability improvement of mycophenolic acid through amino ester derivatization. Pharm Res 1990: 7: 161.
4. Pfitzmann R, Klupp J, Langrehr JM et al. Mycophenolatemofetil for immunosuppression after liver transplantation: A follow-up study of 191 patients. Transplantation 2003: 76: 130.
5. Moreno JM, Rubio E, Gomez A, et al. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation. Transplant Proc 2003: 35: 1874.
6. Moreno Planas JM, Cuervas-Mons Martinez V, Rubio Gonzalez E et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004: 4: 1650.
7. Mc Diarmid SV. Mycophenolate mofetil in liver transplantation. Clin Transplant 1996: 10: 140.
8. Tredger JM, Brown NW, Adams J et al. Monitoring mycophenolate in liver transplant recipients: Toward a therapeutic range. Liver Transpl 2004: 10: 492.
9. Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001: 357: 587.
10. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001: 357: 609.
11. Raimondo ML, Dagher L, Papatheodoridis GV et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003: 75: 186.
12. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: A single center experience. Liver Transpl 2004: 10: 1189.
13. Pierini A, Mirabella S, Brunati A, Ricchiuti A, Franchello A, Salizzoni M. Mycophenolate mofetil monotherapy in liver transplantation. Transplant Proc 2005: 37: 2614.
14. Evans HM, Mc Kiernan PJ, Kelly DA. Mycophenolate mofetil for renal dysfunction after pediatric liver transplantation. Transplantation 2005: 79: 1575.
15. Reich DJ, Clavien PA, Hodge EE. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: Randomized, prospective, multicenter pilot study results. Transplantation 2005: 80: 18.
16. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003: 3: 534.
17. Ying C, De Clercq E, Neyts J. Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. Antiviral Res 2000: 48: 117.
18. Gong ZJ, De Meyer S, Clarysse C et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat 1999: 6: 229.
19. Bahra M, Neumann UI, Jacob D et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: Impact on histological course. Am J Transplant 2005: 5: 406.